Today: 31 May 2026
Browse Category

NASDAQ:CPRX 15 December 2025 - 30 December 2025

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals confirmed CEO Rich Daly will present at the J.P. Morgan Healthcare Conference on January 12, 2026. CPRX traded near $23.95 Monday, below the $26.58 technical level watched by traders. Shares saw volume around 822,000 and a Relative Strength Rating increase from 61 to 73. Analysts cited ongoing debate over the stock’s next move after a strong year.
15 December 2025
·

Stock Market Today

  • T. Rowe Price Group (TROW) Stock Shows Mixed Returns with Potential Undervaluation
    May 31, 2026, 3:52 AM EDT. T. Rowe Price Group (TROW) has delivered mixed returns: a 15.7% gain over one year but a 32.1% decline over five years. The stock trades around $103.55, up 2.8% over the last month, yet down 1.0% year-to-date. Valuation analysis using the Excess Returns model suggests the stock is 37.4% undervalued, with an intrinsic value estimate of about $165.30 per share versus its current price. The model considers an average Return on Equity of 17.23% against a cost of equity of $3.98 per share, indicating shareholders earn excess returns on their investment. Investors are closely re-evaluating TROW amid its mixed medium-to-long term performance and shifts in asset management industry dynamics.

Latest articles

Realty Income Stock Dips Ahead of Jobs Data; Dividend Investors Eye Rates

Realty Income Stock Dips Ahead of Jobs Data; Dividend Investors Eye Rates

31 May 2026
Realty Income closed Friday at $61.28, down from $62.02 the previous week, as property stocks lagged broader market gains. The company declared a $0.2705 monthly dividend, payable June 15 to shareholders of record May 29. CEO Sumit Roy will present at Nareit’s REITweek on June 3. Investors await the U.S. May jobs report on June 5.
Oklo Stock Higher After Plutonium-Fuel Update

Oklo Stock Higher After Plutonium-Fuel Update

31 May 2026
Oklo shares closed at $66.88 Friday, down 1.78%, after a week of gains sparked by news the U.S. Department of Energy selected the company for advanced talks on using surplus plutonium as reactor fuel. Trading volume reached 27.67 million shares. Oklo reported a first-quarter net loss of $33.1 million and ended March with $2.54 billion in cash and equivalents.
Cameco Stock Is Back in Focus After a Mine Restart — What Investors Watch Next

Cameco Stock Is Back in Focus After a Mine Restart — What Investors Watch Next

31 May 2026
Cameco shares closed Friday at C$154.91 on the TSX, up 7.1% for the week after full production resumed at McArthur River and Key Lake following flood-related disruptions. The company kept its 2026 uranium output guidance unchanged at 19.5–21.5 million pounds. CIBC and National Bank of Canada maintained “Outperform” ratings. Cameco reported Q1 net earnings of C$131 million earlier in May.
Go toTop